RT Journal Article
SR Electronic
T1 Associations of prenatal and postnatal growth with insulin-like growth factor-I levels in pre-adolescence
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 144493
DO 10.1101/144493
A1 R Arathimos
A1 C Macdonald-Wallis
A1 CJ Bull
A1 JMP Holly
A1 E Oken
A1 MS Kramer
A1 N Gusina
A1 N Bogdanovich
A1 K Vilchuck
A1 R Patel
A1 R M Martin
A1 K Tilling
YR 2017
UL http://biorxiv.org/content/early/2017/05/31/144493.abstract
AB Background Rapid pre- and postnatal growth have been associated with later life adverse health outcomes, which could implicate (as a mediator) circulating insulin-like-growth-factor I (IGF-I), an important regulator of growth. We investigated associations of prenatal (birth weight and length) and postnatal growth in infancy and childhood with circulating IGF-I measured at 11.5 years of age.Methods We analysed 11.5-year follow-up data from 17,046 Belarusian children who participated in the Promotion of Breastfeeding Intervention Trial (PROBIT) since birth.Results Complete data were available for 5422 boys and 4743 girls (60%). We stratified the analyses by sex, as there was evidence of interaction between growth and sex in their associations with IGF-I. Weight and length/height velocity during childhood were positively associated with IGF-I at 11.5 years; associations increased with age at growth assessment and were stronger for length/height gain than for weight gain. The change in internal run-normalized IGF-I z-score at 11.5 years was 0.038 (95% CI -0.004,0.080) per standard deviation (SD) increase in length gain at 0-3 months amongst girls and 0.025 (95% CI - 0.011,0.060) amongst boys, increasing to 0.336 (95% CI 0.281,0.391;) and 0.211 (95% CI 0.165,0.256) for girls and boys, respectively, for growth during 6.5-11.5 years.Conclusion Postnatal growth velocities in childhood are positively associated with levels of circulating IGF-I in pre-adolescents. Future studies should focus on assessing whether IGF-I is on the causal pathway between early growth and later health outcomes, such as cancer and diabetes.Sources of support Sources of support: PROBIT was supported by grants from the Canadian Institutes of Health Research (MOP - 53155), the US National Institute of Child Health and Development (R01 HD 050758), and the European Union’s project on Early Nutrition Programming: Longterm Efficacy and Safety Trials (FOOD-DT-2005-007036). Dr. Oken was supported by US National Institutes of Health (K24 HD069408, P30 DK092924). The Integrated Epidemiology Unit is supported by the MRC and the University of Bristol (MC_UU_12013_2, MC_UU_12013_5 and MC_UU_12013_8). The NIHR Bristol Nutrition Biomedical Research Unit (RMM) is funded by the National Institute for Health Research (NIHR) and is a partnership between University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. We are grateful to Dr Ying Foo for her help during the design and set up of the Promotion of Breastfeeding Intervention Trial (PROBIT).Trial registration: Current Controlled Trials: ISRCTN37687716; Clinicaltrials.gov: NCT01561612